Breaking News Headlines Today | Ground News

See every side of every news story

endpoints.news image

News from endpoints.news

endpoints.news’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

endpoints.news’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about endpoints.news

Where is endpoints.news located?endpoints.news's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top endpoints.news News

Blow for UK drugs sector as Merck scraps £1bn expansion — REUTERS / ixx511

UK Economy · United Kingdom

Blow for UK drugs sector as Merck scraps £1bn expansion

36% Left coverage: 25 sources

US pharmaceutical giant Merck is scrapping a planned £1bn expansion of its UK operations, saying the government is not investing enough in the sector. The multi-national business, known as MSD in Europe, said it would move its life sciences research to the US and cut UK jobs, blaming successive governments for undervaluing innovative medicines.See the Story

AstraZeneca pauses $270 million investment in Britain — REUTERS / ixx511

AstraZeneca · United Kingdom

AstraZeneca pauses $270 million investment in Britain

45% Center coverage: 18 sources

Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Britain.See the Story

Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs

Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs

100% Center coverage: 4 sources

Novartis is paying $120 million up front to secure rights to a Monte Rosa molecular glue degrader drug candidate as well as options for two others. The two companies began working together last year under an alliance focused on immune mediated-diseases.See the Story

Breaking News Topics Related to endpoints.news